Afleveringen
-
What do you do if you have a family history of dementia and are experiencing symptoms, but can’t get a diagnosis? Dr. Sara Langer has dealt with just that. In the latest episode of our Voices of Research Participants series, Dr. Langer shares the obstacles she endured to receive her diagnosis of Lewy body dementia (LBD), how her background as a neurologist influenced her search for clinical care and how she turned to dementia research to find answers. She also discusses ways that the field of dementia research could improve to support those with other forms of dementia outside of Alzheimer’s disease.
Guest: Sara Langer, MD, neurologist
Co-host: Sarah Walter, MSc, program administrator, Alzheimer’s Clinical Trials Consortium (ACTC) and Alzheimer’s Therapeutic Research Institute (ATRI)
Show NotesLearn more about Sarah Walter at her bio on the Alzheimer’s Clinical Trials Consortium website.
Listen to the first episode of the Voices of Research Participants series, “From Caregiver to Research Participant: How One Woman’s Experience as a Dementia Caregiver Drew Her to Alzheimer’s Research,” on our website, Spotify, Apple Podcasts and all podcast platforms.
Learn more about Lewy body dementia by watching the 2021 Dr. Daniel I. Kaufer Lecture, “Diagnosis and Management of Dementia with Lewy Bodies,” on our YouTube page.
Learn more about how to get a dementia diagnosis on our website.
Connect with UsFind transcripts and more at our website.
Email Dementia Matters: [email protected]
Follow us on Facebook and Twitter.
Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.
Enjoy Dementia Matters? Consider making a gift to the Dementia Matters fund through the UW Initiative to End Alzheimer’s. All donations go toward outreach and production.
-
The brain is the most complex part of the human body, controlling thought, memory, emotion, motor skills, sensory input and all the processes that regulate our bodies. How exactly does it work, and how are clinicians able to determine whether brain changes are a result of normal aging, Alzheimer’s disease, or something else? Dr. Victoria Williams joins the podcast to explain important concepts in neuropsychology, from the difference between cognition and intelligence to how memories are made, and discuss how cognitive tests work in memory clinics.
Guest: Victoria Williams, PhD, neuropsychologist, UW Health, assistant professor, Department of Medicine, University of Wisconsin School of Medicine and Public Health
Show NotesAre you a clinician interested in receiving continuing education (CE) credits for listening to this episode? Find credit designation information, disclosures and evaluation information on our website and on the UW–Madison Interprofessional Continuing Education Partnership (ICEP) website. The accreditation for this course expires 3/25/2025. After this date, you will no longer be able to access the course or claim credit.
Learn more about the domains and structure of the brain through the National Institute of Neurological Disorders and Stroke (NINDS) website.
Learn more about Dr. Williams at her bio on the University of Wisconsin Department of Medicine website.
Connect with UsFind transcripts and more at our website.
Email Dementia Matters: [email protected]
Follow us on Facebook and Twitter.
Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.
Enjoy Dementia Matters? Consider making a gift to the Dementia Matters fund through the UW Initiative to End Alzheimer’s. All donations go toward outreach and production.
-
Zijn er afleveringen die ontbreken?
-
Since the COVID-19 pandemic was declared by the World Health Organization (WHO) in 2020, there have been many concerns about how cases of COVID-19 and Long COVID or Post-COVID Conditions (PCC) affect not just a person’s physical health, but their cognition as well. In this episode, Dr. Jim Jackson talks about his path into critical illness research and his dedicated focus on unraveling the impact of Long COVID on cognition. Throughout the discussion, he talks about the parallels between Long COVID and other chronic illnesses, the effects of Long COVID across different demographics, the concurrent challenges faced by older adults and more.
Guest: James “Jim” Jackson, PsyD, director of long-term outcomes, Critical Illness, Brain Dysfunction, and Survivorship (CIBS) Center, research associate professor of medicine, director of behavioral health, ICU Recovery Center, Vanderbilt University Medical Center
Show NotesLearn more about Dr. Jackson’s book, Clearing the Fog: From Surviving to Thriving with Long Covid―A Practical Guide, on Goodreads.
Listen to Dr. Jackson’s interview on NPR’s Fresh Air podcast, “Millions of people have long COVID brain fog — and there's a shortage of answers.”
Learn more about Dr. Jackson at his bio on the Vanderbilt University website.
Learn more about Long COVID or Post-COVID Conditions on the Centers for Disease Control and Prevention (CDC) website.
Connect with UsFind transcripts and more at our website.
Email Dementia Matters: [email protected]
Follow us on Facebook and Twitter.
Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.
Enjoy Dementia Matters? Consider making a gift to the Dementia Matters fund through the UW Initiative to End Alzheimer’s. All donations go toward outreach and production.
-
Hearing loss affects roughly 15.5% of Americans 20 years and older. While the majority of these individuals experience mild hearing loss, the prevalence and severity of hearing loss increases with age. What does this sensory change mean for dementia risk, and can this risk be prevented through interventions like hearing aids? Dr. Frank Lin joins the podcast to discuss the relationship between hearing loss and dementia and share findings from the Aging and Cognitive Health Evaluation in Elders, or ACHIEVE, study.
Guest: Frank Lin, MD, PhD, director, Cochlear Center for Hearing and Public Health, Professor of Otolaryngology, Medicine, Mental Health, and Epidemiology, Johns Hopkins University
Show NotesRead more about Dr. Lin’s study, “Hearing intervention versus health education control to reduce cognitive decline in older adults with hearing loss in the USA (ACHIEVE): a multicentre, randomised controlled trial,” in The Lancet.
Learn more about the Atherosclerosis Risk in Communities (ARIC) study, mentioned at 20:01, through the National Heart, Lung, and Blood Institute and Johns Hopkins Bloomberg School of Public Health’s websites.
Read more about U.S. regulations surrounding over-the-counter hearing aids, mentioned at 34:00, in “‘A New Frontier’ for Hearing Aids,” by The New York Times.
Learn more about Dr. Lin at his bio on the Johns Hopkins Bloomberg School of Public Health website.
Learn more about the ACHIEVE study on their webpage.
Connect with usFind transcripts and more at our website.
Email Dementia Matters: [email protected]
Follow us on Facebook and Twitter.
Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.
Enjoy Dementia Matters? Consider making a gift to the Dementia Matters fund through the UW Initiative to End Alzheimer’s. All donations go toward outreach and production.
-
Caring for a loved one with cognitive decline can be challenging. While it is a labor of love, burnout is all but inevitable. In this episode kicking off our Voices of Research Participants series with co-host Sarah Walter, Cynthia Sierra touches on her personal experience with caregiver burnout as both a caregiver and research study partner for her mother, who has early-onset Alzheimer’s disease. She also shares her unique perspective on Alzheimer’s disease research as someone who started as a family caregiver.
Guest: Cynthia Sierra, MS, LPC, senior project manager, UT Health San Antonio
Co-host: Sarah Walter, MSc, program administrator, Alzheimer’s Clinical Trials Consortium (ACTC) and Alzheimer’s Therapeutic Research Institute (ATRI)
Show NotesLearn more about Cynthia Sierra’s research at her ResearchGate profile.
Learn more about Sarah Walter at her bio on the Alzheimer’s Clinical Trials Consortium website.
Find resources for people with dementia and their care partners on our website.
Connect with UsFind transcripts and more at our website.
Email Dementia Matters: [email protected]
Follow us on Facebook and Twitter.
Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.
Enjoy Dementia Matters? Consider making a gift to the Dementia Matters fund through the UW Initiative to End Alzheimer’s. All donations go toward outreach and production.
-
In the past few years, new therapies shown to slow the progression of Alzheimer's disease in people in the early stages of the disease have been making their way through the U.S. Food and Drug Administration’s (FDA) approval process. With these treatments now available, there are a growing number of questions surrounding who is eligible to take these medications and what processes are needed to ensure they are prescribed safely and effectively. Host Dr. Nathaniel Chin examines the guidelines for geriatricians and clinicians prescribing lecanemab and breaks down the eligibility requirements necessary to receive this treatment.
Show NotesRead Eisai/Biogen’s “Prescribing Information” for Leqembi online.
Read “Lecanemab: Appropriate Use Recommendations” on the National Library of Medicine website.
Read the U.S. Department of Veterans Affairs’ (VA) guidelines for prescribing lecanemab, “Lecanemab-irmb (LEQEMBI) Criteria for Use August 2023,'' online.
Listen to previous Dementia Matters episodes on lecanemab, including “Putting Lecanemab into Practice: A Clinician’s Perspective on the New Alzheimer’s Treatment,” “A Closer Look at the Lecanemab Clinical Trials,” and “Introducing Lecanemab, The Latest Alzheimer’s Disease Drug to Receive FDA Accelerated Approval,” on our website and all major podcast platforms.
Connect with UsFind transcripts and more at our website.
Email Dementia Matters: [email protected]
Follow us on Facebook and Twitter.
Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.
Enjoy Dementia Matters? Consider making a gift to the Dementia Matters fund through the UW Initiative to End Alzheimer’s. All donations go toward outreach and production.
-
In 2017, the National Academies of Sciences, Engineering, and Medicine published a report showing promising but inconclusive evidence suggesting that interventions like cognitive training, blood pressure control and increased physical activity reduce a person’s risk for dementia, but what does the research show now? Dr. Luke Stoeckel from the National Institute on Aging (NIA) joins the podcast to share where the research on lifestyle interventions is at, why studies on these interventions are difficult to complete and more.
Guest: Luke Stoeckel, PhD, program director, Mechanistic and Translational Decision Science Program, Division of Behavioral and Social Research (DBSR), NIA
Show NotesLearn about the National Academies of Sciences, Engineering, and Medicine on their website.
Read the 2017 National Academies’ report, “Preventing Cognitive Decline and Dementia,” for free on their website.
Learn about the National Academies’ Research Priorities for Preventing and Treating Alzheimer’s Disease and Related Dementias and find upcoming workshops on their website.
Find information on the 2021 National Academies workshop mentioned by Dr. Chin at 1:36 on the National Academies website.
Learn more about Dr. Stoeckel in his bio on the National Institute on Aging website.
Connect with UsFind transcripts and more at our website.
Email Dementia Matters: [email protected]
Follow us on Facebook and Twitter.
Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.
Enjoy Dementia Matters? Consider making a gift to the Dementia Matters fund through the UW Initiative to End Alzheimer’s. All donations go toward outreach and production.
-
In this year-end episode of Dementia Matters, we explore the vital role of philanthropy in advancing Alzheimer's disease research and care. Mr. Dave Adam serves on the board of visitors for the UW Initiative to End Alzheimer’s (IEA) and is an avid long-distance biker. In this episode, Adam shares his journey of combining his passions for biking and Alzheimer's advocacy. With personal experiences touched by dementia, Dave discusses how he used his solo biking expeditions across Canada and Australia to raise awareness and funds to support prevention and treatment strategies, improve care and benefit researchers at the University of Wisconsin–Madison seeking a cure for Alzheimer’s disease.
Guest: Dave Adam, board of visitors, UW Initiative to End Alzheimer’s (IEA)
Show NotesDo you like what you are hearing and learning? Make an impact when you make a tax-deductible gift to the Dementia Matters fund of the UW Initiative to End Alzheimer’s. All donations go toward outreach and production.
Learn more about UW Initiative to End Alzheimer’s (IEA) on its website.
Read more about Mr. Adam’s travel and biking stories on his website.
Learn more about Mr. Adam on the UW Initiative to End Alzheimer’s website.
Connect with usFind transcripts and more at our website.
Email Dementia Matters: [email protected]
Follow us on Facebook and Twitter.
Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.
-
Dr. Paul Seidler joins the podcast to discuss his recent study looking at the connection between molecules in green tea and tau proteins. He also discusses the impact those molecules have on preventing cognitive decline and how these findings could lead to new strategies for treating Alzheimer’s disease.
Guest: Paul Seidler, PhD, assistant professor, University of Southern California Mann School of Pharmacy and Pharmaceutical Sciences
Show NotesRead more about Dr. Seidler’s study, “Structure-based discovery of small molecules that disaggregate Alzheimer's disease tissue derived tau fibrils in vitro,” on the National Library of Medicine website.
Read the article on the research from the National Institute on Aging (NIA), “Study of green tea and other molecules uncovers new therapeutic strategy for Alzheimer’s,” on their website.
Learn more about Dr. Seidler on the University of Southern California’s website.
Connect with usFind transcripts and more at our website.
Email Dementia Matters: [email protected]
Follow us on Facebook and Twitter.
Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.
-
In May 2023, the U.S. Surgeon General, Dr. Vivek Murthy, released an advisory calling attention to the public health crisis of loneliness and social isolation in the U.S. With this widespread issue affecting such a broad population, how does social isolation impact older adults? Dr. Alison Huang joins the podcast to share insights from her study on the relationship between social isolation and the risk of dementia in older adults. Using data from a nine-year National Health and Aging Trends Study (NHATS), she discusses how factors like living alone, limited social networks and reduced activity participation contribute to increased dementia risk.
Guest: Alison Huang, PhD, MPH, senior research associate, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health
Show NotesLearn more about the U.S. Surgeon General’s 2023 advisory, Our Epidemic of Loneliness and Isolation, on the U.S. Department of Health and Human Services (HHS) website.
Read Dr. Huang’s study, “Social isolation and 9-year dementia risk in community-dwelling Medicare beneficiaries in the United States,” on the Journal of the American Geriatrics Society website.
Learn more about the National Health and Aging Trends Study (NHATS) on their website.
Learn more about Dr. Alison Huang on Johns Hopkins Cochlear Center for Hearing and Public Health’s website.
Learn more about Alzheimer's disease prevention on our website.
Connect with usFind transcripts and more at our website.
Email Dementia Matters: [email protected]
Follow us on Facebook and Twitter.
Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.
-
Six years following the start of Dementia Matters in October 2017, the podcast team turns the tables on our host, Dr. Nathaniel Chin. Producers Amy Lambright Murphy and Caoilfhinn Rauwerdink talk with Dr. Chin about how the podcast got started, the brain health tips he incorporates into his own life, how he envisions the field of Alzheimer’s disease research advancing in the next five years and other personal insights from the person behind the podcast.Guest: Nathaniel Chin, MD, geriatrician, medical director, Wisconsin Alzheimer’s Disease Research Center, Wisconsin Registry for Alzheimer’s Prevention, host, Dementia Matters
Show NotesVisit our “Prevention” webpage for more on the brain health tips mentioned at 7:07.
Listen to our episode, “Highlights from the 2023 Alzheimer’s Association International Conference,” referenced at 10:49, on our website, Spotify, Apple Podcasts, or wherever you get your podcasts.
Learn more about the importance of a healthy diet, mentioned at 8:25, by watching, “Take Care of Your MIND: Reviewing the MIND Diet for Healthy Brain Aging,” on our YouTube channel.
Connect with usFind transcripts and more at our website.
Email Dementia Matters: [email protected]
Follow us on Facebook and Twitter.
Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.
-
Cognitive engagement is vital to keeping your brain healthy since it can slow shrinkage and induce neuroplasticity. While modern technology offers many new tools and games to keep your brain active, are they better than traditional puzzles like crosswords? Dr. Murali Doraiswamy of Duke University joins the podcast to talk about his recent study, in collaboration with principal investigator Dr. Dev Devanand of Columbia University, on the effects of daily crossword puzzles on the brain health of older adults in comparison to daily computerized games.
Guest: P. Murali Doraiswamy, MBBS, FRCP, director, Neurocognitive Disorders Program, physician scientist, Duke Institute for Brain Sciences, professor of psychiatry and medicine, Duke University School of Medicine, co-author, The Alzheimer’s Action Plan
Show NotesLearn more about Dr. Doraiswamy on Duke University Department of Medicine’s website.
Read Drs. Devanand and Doraiswamy's study, “Computerized Games versus Crosswords Training in Mild Cognitive Impairment,” through the New England Journal of Medicine Evidence.
Connect with usFind transcripts and more at our website.
Email Dementia Matters: [email protected]
Follow us on Facebook and Twitter.
Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.
-
Dementia caregiving is a multifaceted domain, deeply influenced by research, strategy and personal experiences. How are these elements shaping the current and future landscape of care? Dr. Beth Fields joins the podcast to discuss strategies and resources for caregivers from both national, state and personal perspectives, including the CHAT tool, the CAPABLE program and the National Strategy to Support Family Caregivers.
Guest: Beth Fields, PhD, board-certified occupational therapist, assistant professor, Department of Kinesiology, affiliate faculty member, Center for Aging Research and Education and Wisconsin Alzheimer's Disease Research Center, University of Wisconsin–Madison
Show NotesAre you a clinician interested in receiving continuing education (CE) credits for listening to this episode? Find credit designation information, disclosures and evaluation information on our website and on the UW–Madison Interprofessional Continuing Education Partnership (ICEP) website. The accreditation for this course expires 10/9/2024. After this date, you will no longer be able to access the course or claim credit.
Learn more about the RAISE 2022 National Strategy to Support Family Caregivers on the Administration for Community Living’s website.
Read Dr. Fields’ studies on the CHAT tool and CAPABLE program.
Learn more about family caregiver support resources on Trualta’s website.
Visit Wisconsin’s Family Caregiver Support Programs at wisconsincaregiver.org.
Listen to our episode with Dr. Arthur Kleinman, “Exploring the Lessons Learned as a New Caregiver” mentioned at 24:48, on our website, Spotify, Apple Podcasts, Podbean, or wherever you listen.
Learn more about Dr. Fields on the UW Department of Kinesiology’s website.
Connect with usFind transcripts and more at our website.
Email Dementia Matters: [email protected]
Follow us on Facebook and Twitter.
-
Like cognition, mental health is a key component of the brain — and overall — health. In what ways can mental health and chronic mental illness impact a person’s cognition and risk for dementia? Dr. Art Walaszek joins the podcast to discuss the relationships between dementia and chronic mental illnesses, including major depression, bipolar disorder and schizophrenia in older adults.
Guest: Art Walaszek, MD, geriatric psychiatrist, professor, vice chair for education and faculty development, Department of Psychiatry, University of Wisconsin School of Medicine and Public Health
Show NotesAre you a clinician who’s interested in receiving continuing education (CE) credit for listening to this episode? Find credit designation information, disclosures, and evaluation information on our website and on the UW-Madison Interprofessional Continuing Education Partnership (ICEP) website. The accreditation for this course expires 9/18/2024. After this date, you will no longer be able to access the course or claim credit.
If you or a loved one are struggling with mental health or are experiencing a mental health crisis, please reach out to the 988 Suicide & Crisis Lifeline by calling or texting 988.
Learn more about Dr. Walaszek on the UW Department of Psychiatry’s website.
Connect with usFind transcripts and more at our website.
Email Dementia Matters: [email protected]
Follow us on Facebook and Twitter.
Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.
-
The 2023 Alzheimer's Association International Conference (AAIC) in Amsterdam brought together the world's leading scientists, clinical researchers, early career investigators, caregiving researchers and more to discuss the latest findings and advancements in dementia science. Dr. Percy Griffin joins the podcast to share key highlights from the conference. He discusses the use of CRISPR technology in Alzheimer's research, the significance of defining Alzheimer's by its biology rather than its symptoms and how the field is moving toward a precision medicine approach.
Guest: Percy Griffin, PhD, director of scientific engagement, Alzheimer’s Association
Show NotesLearn more about the Wisconsin Alzheimer’s Disease Research Center’s Fall Community Conversation on our website, and watch the livestream on our YouTube page.
AAIC is the world’s largest forum dedicated to advancing dementia research. Find more highlights from the conference, including on-demand content that is available to watch through September 20, 2023, at 11:59 p.m. CT, on the AAIC website.
Find news highlights on CRISPR technology, county-level prevalence data on Alzheimer's, the ACHIEVE study and more mentioned by Dr. Griffin on the AAIC website.
Listen to our AAIC 2022 highlights episode with Dr. Griffin, mentioned at 1:15, on our website, Spotify, Apple Podcasts, YouTube, or wherever you listen.
Learn more about Dr. Griffin in his bio on the Alzheimer’s Association’s website.
Connect with usFind transcripts and more at our website.
Email Dementia Matters: [email protected]
Follow us on Facebook and Twitter.
Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.
-
How can we ensure that all communities are represented in Alzheimer’s and related dementias research and have access to the latest treatments and interventions? Dr. Carl Hill, the chief diversity, equity and inclusion (DEI) officer for the Alzheimer's Association, joins the podcast to delve into the significance of representation, diversity, equity, equality and inclusion within Alzheimer's disease research. He discusses the challenges of underrepresentation in clinical trials, the importance of community-based participatory research (CBPR) and the social determinants of health that influence Alzheimer's risk.
Guest: Carl V. Hill, PhD, MPH, chief diversity, equity and inclusion officer, Alzheimer's Association
Show NotesLearn more about the Alzheimer’s Association’s effort in DEI from their inaugural DEI report.
Learn more about race-related topics in Alzheimer’s disease from the Alzheimer’s Association International Conference (AAIC) 2022 here, including a study on the impact of racism on the brain and findings on racial disparities in health equity and resources in Black and Brown communities.
Listen to Dr. Hill’s past episodes of Dementia Matters, “Scientific Importance Of Diversity In Alzheimer’s Disease Research,” and, “Battling Health Disparities In Aging Research And Care,” on our website.
Learn more about Dr. Hill in his bio on the Alzheimer’s Association’s website.
Connect with usFind transcripts and more at our website.
Email Dementia Matters: [email protected]
Follow us on Facebook and Twitter.
Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.
-
Many people living with dementia experience behavioral symptoms alongside changes in their cognition. What can care partners and healthcare providers do to manage these behavioral changes? After leading the Wisconsin Alzheimer’s Disease Research Center’s (ADRC) annual Dr. Daniel I. Kaufer Lecture, Dr. Helen Kales joins the podcast to discuss agitation and other behavioral symptoms of dementia, the use of medications to manage these symptoms, and different caregiving approaches for addressing these behavioral changes in people living with dementia.
Guest: Helen Kales, MD, geriatric psychiatrist, Joe P. Tupin Endowed Professor of Psychiatry, Chair, Department of Psychiatry and Behavioral Sciences, University of California, Davis
Show NotesWatch the recording of Dr. Kales’ lecture, "Agitation is not a disease: How can we better manage the behavioral and psychological symptoms of dementia?,” on YouTube.
Learn more about the DICE approach, discussed at 21:01, on The DICE Approach website.
Learn more about the annual Dr. Daniel I. Kaufer Lecture on our website.
Learn more about Dr. Kales at her bio on the University of California, Davis website.
Connect with usFind transcripts and more at our website.
Email Dementia Matters: [email protected]
Follow us on Facebook and Twitter.
Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.
-
Gina Green-Harris joins the podcast to discuss the importance of collaborating with communities in Alzheimer’s research. Sharing her experience as a researcher with the Wisconsin Alzheimer’s Institute (WAI) and the All of Us research program, she describes the key tenets of community engagement and explains ways researchers can build intentional, sustainable partnerships with communities throughout the research process This episode is part of a series featuring speakers from the National Alzheimer’s Coordinating Center’s (NACC) Fall 2022 ADRC Meeting, where the overarching theme was Diversity, Equity, and Inclusion (DEI) in ADRC research and operations.
Guest: Gina Green-Harris, MBA, director, Wisconsin Alzheimer’s Institute Regional Milwaukee Office, co-primary investigator, co-director, University of Wisconsin–Madison’s All of Us research program
Show NotesLearn more about Gina Green-Harris on the Wisconsin Alzheimer’s Institute’s website and on the UW Institute for Clinical and Translational Research’s website.
Learn more about the All of Us Research Program.
Watch a recording of Gina Green-Harris’s talk at NACC’s Fall 2022 Alzheimer’s Disease Research Center.
Learn more about the National Alzheimer’s Coordinating Center at their website.
Connect with usFind transcripts and more at our website.
Email Dementia Matters: [email protected]
Follow us on Facebook and Twitter.
Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.
-
The APOE gene is recognized as a significant genetic risk factor for cognitive decline, with different alleles, like APOE e2, being seen as protective against decline and others, like APOE e4, indicating an increased risk for cognitive decline. However, new studies are looking at whether these trends are universal across different racial and ethnic groups. Dr. Cally Xiao joins the podcast to discuss her study, which focuses on how different APOE alleles affect risk for Alzheimer’s disease within Hispanic populations compared to non-Hispanic populations.
Guest: Cally Xiao, PhD, Project Specialist, Global Alzheimer’s Association Interactive Network, Laboratory of Neuro Imaging, University of Southern California
Show NotesFollow Dr. Xiao on Twitter.
Learn more about GAAIN on their website or on Twitter.
Read more about the study, “Comparison of genetic and health risk factors for mild cognitive impairment and Alzheimer's disease between Hispanic and non-Hispanic white participants,” online through the journal Alzheimer’s and Dementia.
Listen to Sarah Biber’s episode, “The Future Of Sharing And Accessing Alzheimer’s Disease Data,” on our website, Spotify, Apple Podcasts, Podbean, and all major podcast platforms.
Connect with usFind transcripts and more at our website.
Email Dementia Matters: [email protected]
Follow us on Facebook and Twitter.
Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.
-
On July 6, 2023, the U.S. Food and Drug Administration (FDA) granted full approval for the Alzheimer’s disease drug Leqembi (lecanemab-irmb), the first medicine shown to delay the course of the disease. Having gone through a rigorous approval process, the medication exemplifies a critical advancement in the ongoing battle to treat Alzheimer’s disease. Having already prescribed the treatment to real-life patients, Dr. Robert Przybelski joins the podcast to discuss his experience prescribing and administering lecanemab, what clinicians and patients should discuss when considering these treatments, and what is needed to integrate these treatments into the healthcare system.
Guest: Robert Przybelski, MD, MS, director, Geriatric Memory Clinics, UW Health, professor, Division of Geriatrics and Gerontology, University of Wisconsin School of Medicine and Public Health
Show NotesRead more about Lecanemab’s Appropriate Use Guidelines on our website.
Read the FDA’s press release, “FDA Converts Novel Alzheimer’s Disease Treatment to Traditional Approval.”
Listen to previous Dementia Matters episodes on lecanemab, “Introducing Lecanemab, The Latest Alzheimer’s Disease Drug to Receive FDA Accelerated Approval,” and “A Closer Look at the Lecanemab Clinical Trials,” on our website and all major podcast platforms.
Listen to Dr. Przybelski’s previous episode of Dementia Matters, “Vitamin Deficiency And Its Impact On Brain Health,” on our website, Spotify, Apple Podcasts, Podbean, and all major podcast platforms.
Connect with usFind transcripts and more at our website.
Email Dementia Matters: [email protected]
Follow us on Facebook and Twitter.
Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.
- Laat meer zien
